Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Acumen Pharmaceuticals Inc Is A Clinical-Stage Biopharmaceutical Company Developing A Novel Disease-Modifying Approach To Target What It Believes To Be A Key Underlying Cause Of Alzheimer'S Disease. The Company'S Drug Candidate, Acu193, Is A Subclass Monoclonal Antibody That Selectively Targets Amyloid-Beta Oligomers. The Product Pipelines Include: Altitude-Ad; And Intercept-Ad.